IL286343A - Anti-cd38 antibodies and pharmaceutical preparations thereof for the treatment of autoantibody-mediated autoimmune disease - Google Patents

Anti-cd38 antibodies and pharmaceutical preparations thereof for the treatment of autoantibody-mediated autoimmune disease

Info

Publication number
IL286343A
IL286343A IL286343A IL28634321A IL286343A IL 286343 A IL286343 A IL 286343A IL 286343 A IL286343 A IL 286343A IL 28634321 A IL28634321 A IL 28634321A IL 286343 A IL286343 A IL 286343A
Authority
IL
Israel
Prior art keywords
autoantibody
antibodies
treatment
pharmaceutical compositions
autoimmune disease
Prior art date
Application number
IL286343A
Other languages
English (en)
Hebrew (he)
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of IL286343A publication Critical patent/IL286343A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL286343A 2019-03-15 2021-09-13 Anti-cd38 antibodies and pharmaceutical preparations thereof for the treatment of autoantibody-mediated autoimmune disease IL286343A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19163036 2019-03-15
PCT/EP2020/056757 WO2020187718A1 (en) 2019-03-15 2020-03-13 Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease

Publications (1)

Publication Number Publication Date
IL286343A true IL286343A (en) 2021-10-31

Family

ID=65817862

Family Applications (1)

Application Number Title Priority Date Filing Date
IL286343A IL286343A (en) 2019-03-15 2021-09-13 Anti-cd38 antibodies and pharmaceutical preparations thereof for the treatment of autoantibody-mediated autoimmune disease

Country Status (12)

Country Link
US (1) US20220144965A1 (https=)
EP (1) EP3938394A1 (https=)
JP (2) JP7687956B2 (https=)
KR (1) KR20220002891A (https=)
CN (1) CN113574071B (https=)
AU (2) AU2020242228B2 (https=)
CA (1) CA3130132A1 (https=)
IL (1) IL286343A (https=)
MX (1) MX2021011181A (https=)
SG (1) SG11202107319PA (https=)
TW (1) TW202102541A (https=)
WO (1) WO2020187718A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022152823A1 (en) 2021-01-14 2022-07-21 Morphosys Ag Anti-cd38 antibodies and their uses
TW202302642A (zh) * 2021-03-01 2023-01-16 德商莫菲西斯公司 用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體
FR3120866B1 (fr) * 2021-03-19 2025-02-28 Univ Toulouse 3 Paul Sabatier Molécule hybride comprenant un peptide citrulliné dérivé de la fibrine et un anticorps ou fragment d’anticorps se liant à CD38 et/ou CD138, et ses utilisations
TW202321303A (zh) * 2021-07-19 2023-06-01 德商莫菲西斯公司 抗pla2r自體抗體媒介膜性腎病變之治療
CN116183930A (zh) * 2022-12-29 2023-05-30 陕西脉元生物科技有限公司 抗insrr抗体在制备检测和/或诊断神经系统相关疾病的产品中的应用
WO2026080575A1 (en) * 2024-10-08 2026-04-16 Human Immunology Biosciences, Inc. Anti-cd38 antibodies and their uses

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020164788A1 (en) 1994-12-02 2002-11-07 The Wellcome Foundation Limited Humanized antibodies to CD38
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
WO1999062526A2 (en) 1998-06-05 1999-12-09 Mayo Foundation For Medical Education And Research Use of genetically engineered antibodies to cd38 to treat multiple myeloma
US7223397B1 (en) 1999-01-07 2007-05-29 Research Development Foundation Potentiation of anti-CD38-Immunotoxin cytotoxicity
PT2281843T (pt) 2000-06-16 2017-01-02 Human Genome Sciences Inc Anticorpos que se ligam imunoespecificamente a blys
EP1174440A1 (en) 2000-07-19 2002-01-23 U-BISys B.V. A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment
KR20140066259A (ko) 2004-02-06 2014-05-30 모르포시스 아게 항-ｃｄ３８ 인간 항체 및 그의 용도
CN1976950B (zh) * 2004-02-06 2012-08-29 莫佛塞斯公司 抗cd38人抗体及其用途
JP5225069B2 (ja) 2005-03-23 2013-07-03 ゲンマブ エー／エス 多発性骨髄腫の治療のためのｃｄ３８に対する抗体
TW200745162A (en) 2005-05-24 2007-12-16 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
CA2625681C (en) * 2005-10-12 2016-08-02 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38
WO2008037257A2 (en) 2006-09-26 2008-04-03 Genmab A/S Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
HUE027683T2 (en) 2007-10-01 2016-10-28 Codexis Inc Ketoreductase polypeptides for the production of azetidinone
HUE030134T2 (en) 2007-10-16 2017-04-28 Zymogenetics Inc Combination of transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) and anti-CD20 agents for the treatment of autoimmune diseases
EP2191843A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
EP2191841A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
EP2191842A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
EP2191840A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
SMT202000031T1 (it) * 2010-06-09 2020-03-13 Genmab As Anticorpi contro cd38 umano
SG186397A1 (en) * 2010-06-22 2013-01-30 Univ Colorado Regents Antibodies to the c3d fragment of complement component 3
DK2621531T3 (en) * 2010-09-27 2017-02-27 Morphosys Ag ANTI-CD38 ANTIBODY AND LENALIDOMIDE OR BORTEZOMIB FOR TREATMENT OF MULTIPLE MYELOM AND NHL
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
MX368288B (es) * 2012-09-25 2019-09-27 Morphosys Ag Una combinación de anticuerpos anti-cd38 y melfalán para usarse en el tratamiento de mieloma múltiple.
UA118255C2 (uk) * 2012-12-07 2018-12-26 Санофі Композиція, яка містить антитіло до cd38 і леналідомід
EA201792546A1 (ru) * 2015-05-20 2018-04-30 Янссен Байотек, Инк. Антитела к cd38 для лечения амилоидоза легких цепей и прочих cd38-положительных гематологических злокачественных опухолей
WO2017149122A1 (en) 2016-03-04 2017-09-08 Morphosys Ag Clinical assessment of m-protein response in multiple myeloma

Also Published As

Publication number Publication date
US20220144965A1 (en) 2022-05-12
AU2026201243A1 (en) 2026-03-12
WO2020187718A1 (en) 2020-09-24
CA3130132A1 (en) 2020-09-24
CN113574071B (zh) 2025-03-25
NZ777838A (en) 2025-05-02
AU2020242228B2 (en) 2025-12-11
SG11202107319PA (en) 2021-08-30
KR20220002891A (ko) 2022-01-07
TW202102541A (zh) 2021-01-16
JP7687956B2 (ja) 2025-06-03
MX2021011181A (es) 2022-01-19
JP2022524204A (ja) 2022-04-28
CN113574071A (zh) 2021-10-29
AU2020242228A1 (en) 2021-07-22
EP3938394A1 (en) 2022-01-19
JP2025126171A (ja) 2025-08-28

Similar Documents

Publication Publication Date Title
IL286343A (en) Anti-cd38 antibodies and pharmaceutical preparations thereof for the treatment of autoantibody-mediated autoimmune disease
ZA202004025B (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
ZA202110597B (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
IL285782A (en) Compounds, compositions, and methods for treating disease
IL279397A (en) New compounds and their pharmaceutical preparations for the treatment of diseases
IL268007A (en) Anti-TNF antibodies, preparations and methods for the treatment of active psoriatic arthritis
ZA202002166B (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
GB201907558D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
WO2017049038A3 (en) Anti-cd115 antibodies
SG11202003273PA (en) Anti-cd3 antibody and pharmaceutical composition for cancer treatment comprising same
IL279622A (en) Pharmaceutical formulations of masked antibodies
IL287392A (en) New compounds and their pharmaceutical preparations for the treatment of kidney diseases
IL285751A (en) New compounds and their pharmaceutical preparations for the treatment of diseases
GB201702603D0 (en) Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders
HUE053866T2 (hu) Gyógyászati készítmény székrekedés kezelésére
GB201803563D0 (en) Antibodies and pharmaceutical compositions thereof for the treatment of autoimmune skin diseases
IL289734A (en) Preparations and methods for the treatment of Sanfilippo disease and other disorders
GB201817343D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
GB201817344D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
IL286162A (en) Pharmaceutical preparations containing anti-lingo-1 antibodies
GB201809836D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
HK40061757A (en) Clec12axcd3 bispecific antibodies and methods for the treatment of disease
GB201814764D0 (en) Pharmaceutical compositions for the treatment of proteinopathies
GB201720101D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
AU2019900557A0 (en) Anti-integrin antibodies with IL-2 for the treatment of inflammatory bowel disease